Skip to content

Compare U.S. Stocks

Put up to three companies side by side on valuation, growth, profitability, and debt.

MetricBIIBBiogenMRNAModernaINCYIncyte
Snapshot
Price$199.71$59.34$103.66
Market cap$29.02B$25.38B$19.62B
Valuation
P/E21.1x—13.7x
Forward P/E23x—9.8x
Growth
Revenue growth1.2%-30.0%21.5%
EPS growth-8.1%—2455.3%
Profitability
Net margin13.8%-143.6%26.7%
ROE7.5%-36.7%29.2%
Balance sheet & cash
Debt / equity0.34x0.07x0.01x
Free cash flow yield6.8%-13.6%2.2%
Dividend yield———
Verdict
Investment ratingNeutral· 49Weak· 17Strong· 86

5-Year Price Projections

Base case

Projected using each stock's current EPS, growth rate (EPS or revenue growth), and P/E ratio. P/E assumed to compress 25% on the low end and remain steady on the high end. Not a forecast — for comparative analysis only.

YearBIIBtoday $200MRNAtoday $59INCYtoday $104
2027$152.78 – $224.07+12% CAGR$45.40 – $66.59+12% CAGR$1,986.63 – $2,913.72+2711% CAGR
2028$155.83 – $228.56+7% CAGR$46.31 – $67.92+7% CAGR$50,764.45 – $74,454.52+2580% CAGR
2029$158.95 – $233.13+5% CAGR$47.23 – $69.28+5% CAGR$1,297,188.98 – $1,902,543.84+2538% CAGR
2030$162.13 – $237.79+4% CAGR$48.18 – $70.66+4% CAGR$33,147,199.80 – $48,615,893.04+2517% CAGR
2031$165.37 – $242.55+4% CAGR$49.14 – $72.07+4% CAGR$847,013,711.15 – $1,242,286,776.35+2504% CAGR
5-yr CAGR-3.7% – 4.0%-3.7% – 4.0%2312.4% – 2504.5%